A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 19, Issue 11, 2017, Pages 1602-1609

  Gantz, Ira ^a   Okamoto, Taro ^b   Ito, Yuka ^b   Okuyama, Kotoba ^b   O'Neill, Edward A ^a   Kaufman, Keith D ^a   Engel, Samuel S ^a   Lai, Eseng ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Merck Sharp Dohm Res Labs Japan   (Japan)

Author keywords

incretins; MK 3102; oral antihyperglycaemic agent

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; OMARIGLIPTIN; PLACEBO; SITAGLIPTIN; 2-(2,5-DIFLUOROPHENYL)-5-(2-(METHYLSULFONYL)-2,6-DIHYDROPYRROLO(3,4-C)PYRAZOL-5(4H)-YL)TETRAHYDRO-2H-PYRAN-3-AMINE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FUSED HETEROCYCLIC RINGS; PYRAN DERIVATIVE;

ADULT; ARTICLE; BRONCHITIS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTRITIS; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFECTION; INFLUENZA; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; THORAX DISEASE; UPPER RESPIRATORY TRACT INFECTION; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; JAPAN; TREATMENT OUTCOME;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; PLACEBOS; PYRANS; SITAGLIPTIN PHOSPHATE; TREATMENT OUTCOME;

EID: 85021793718     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12988     Document Type: Article

References (18)

1. Biftu T, Sinha-Roy R, Chen P, et al. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once weekly treatment of type 2 diabetes. J Med Chem. 2014;57(8):3205-3212.
2. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007;23(4):919-931.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
4. Liang KY, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Indian J Stat. 2000;62:134-148.
5. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2):213-226.
6. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons; 1987.
7. Goldenberg R, Gantz I, Andryuk PJ, et al. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2017;19(3):394-400.
8. Araki E, Kawamori R, Inagaki N, et al. Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(4):364-371.
9. Konya H, Yano Y, Matsutani S, et al. Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients. Ther Clin Risk Manag. 2014;10:547-558.
10. Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015;14(4):505-524.
11. Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13(2):144-149.
12. Hauber AB, Tunceli K, Yang JC, et al. A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus. Diabetes Ther. 2015;6(1):75-84.
13. Sen R, Shields AL, Atsuda K. Patient preference for once-weekly doseing in type 2 diabetes in Japan. JHEOR. 2013;4(1):55-66.
14. Suzuki D, Kuroki H, Tsukada A, et al. Do patients choose once weekly DPP-4 inhibitors? [Japanese]. Progress Med. 2016;36:389-392.
15. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218-1224.
16. Tunceli K, Zhao C, Davies MJ, et al. Factors associated with adherence to oral antihyperglycemic monotherapy in patients with type 2 diabetes. Patient Prefer Adherence. 2014;9:191-197.
17. Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015;38(4):604-609.
18. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19(4):279-284.